Sweden

InDex Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation

Lead Product(s): Cobitolimod

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Vinnova

Deal Size: $0.1 million Upfront Cash: Undisclosed

Deal Type: Funding March 31, 2020

Details:

The grant will be used for a preclinical project to evaluate selected compounds from InDex's DIMS platform in inflammatory disease models outside the field of inflammatory bowel disease.

Cinclus Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease

Lead Product(s): Linaprazan

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Fourth Swedish National Pension Fund

Deal Size: $25.6 million Upfront Cash: Undisclosed

Deal Type: Financing March 04, 2020

Details:

The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.

InDex Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal

Lead Product(s): Cobitolimod

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 25, 2020

Details:

The paper shows that the Toll-like receptor 9 (TLR9) agonist cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.

InDex Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results

Lead Product(s): Cobitolimod

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 19, 2020

Details:

The Phase IIb dose optimisation study CONDUCT, is evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

InDex Pharmaceuticals

InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation

Cinclus Pharma

Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease

InDex Pharmaceuticals

InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal

InDex Pharmaceuticals

InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results